Phase IIa Clinical Study of SKLB1028 Capsule in the Treatment of FLT3 Mutation Recurrence / Refractory AML Patients
Latest Information Update: 03 Oct 2021
At a glance
- Drugs SKLB 1028 (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 11 Jul 2019 New trial record